Combination expands geographical footprint offering a global one-stop shop solution for streamlined chemical compound procurement and management services for drug discovery chemistry researchers.
24 May 2023 – San Diego, CA, USA and Zoetermeer, The Netherlands
eMolecules, Inc., a provider of an industry leading chemical compound search-and-fulfillment platform for early discovery chemistry research, today announced the acquisition of Specs Compound Handling B.V. (Specs).
Specs offers leading chemical compound management services to the life science industry, particularly in the European pharmaceutical, biotechnology and academic sectors, successfully supporting time- and cost-efficient large scale drug candidate screening programs for its customers.
Headquartered in the Netherlands, Specs has over 35 years of commercial and chemical reformatting operations in Europe and USA, and commercial operations in Asia. The acquisition strategically expands the geographical footprint of eMolecules’ compound reformatting and management capabilities.
“Welcoming the highly reputable and talented Specs team into eMolecules represents a major milestone and opportunity for our companies and customers,” said Dr. Niko Gubernator, CEO and President of eMolecules. “We are thrilled at the prospect of deepening and broadening our relationships with research organizations who have expressed the need for a true, global, end-to-end partner to support efficient compound procurement and management across regionally distributed chemistry groups.”
Dr. Johan Tijhuis, CEO of Specs said, “We are excited to join forces with eMolecules and believe that the combination of our two teams will enhance the value we provide to the drug discovery research community. Specs’ customers greatly appreciate the white-glove support that we offer, especially to those with important chemistry operations in Europe. We are delighted that they will benefit from having access to eMolecules’ expertise in global chemical procurement and expanded reformatting and inventory management services in the US through our facilities.”
Dr. Gubernator also noted, “This acquisition accelerates eMolecules towards our vision of delivering world-class capabilities that support the rapid transformation of chemicals into knowledge. Both eMolecules and Specs are united in the goal to enable chemists to focus on the highest value activities and reduce the inefficiencies associated with drug discovery, resulting in tangible operational returns for our customers.”
eMolecules’ existing investors, including Avista Capital Partners, supported the transaction.
Read the full article here:
